The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial
Abstract
PURPOSE: Treatment options for patients with overactive bladder refractory to anticholinergics are limited. We assessed the dose response across a range of doses of onabotulinumtoxinA (BOTOX®) in patients with idiopathic overactive bladder and urinary urgency incontinence whose symptoms were not adequately managed with anticholinergics. MATERIALS AND METHODS: In a phase 2, multicenter, randomized, double-blind study, 313 patients with idiopathic overactive bladder and urinary urgency incontinence experiencing 8 or more urinary urgency incontinence episodes a week and 8 or more micturitions daily at baseline received 50, 100, 150, 200 or 300 U intradetrusor onabotulinumtoxinA, or placebo. Symptoms were recorded using a 7-day bladder diary. The primary efficacy variable was weekly urinary urgency incontinence episodes and the primary end point was week 12. RESULTS: Demographics and baseline characteristics were balanced across the treatment groups. Durable efficacy was observed for all onabotulinumtoxinA dose groups of 100 U or greater for primary and secondary efficacy measures, including the proportion of incontinence-free patients. When the dose response curves were analyzed, doses greater than 150 U contributed minimal additional or clinically relevant improvement in symptoms. This finding was also reflected in health related quality of life assessments. Dose dependent changes in post-void residual urine volume were observed and the use of clean intermittent catheterization was also dose dependent. The only adverse events significantly greater with onabotulinumtoxinA than with placebo were urinary tract infection and urinary retention. CONCLUSIONS: OnabotulinumtoxinA at doses of 100 U or greater demonstrated durable efficacy in the management of idiopathic overactive bladder and urinary urgency incontinence. A dose of 100 U may be the dose that appropriately balances the symptom benefits with the post-void residual urine volume related safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., van Kerrebroeck, P., Victor, A., & Wein, A. (2002) · Neurourology and Urodynamics · doi:10.1002/nau.10052 · Cited by 8,296
Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., Van Kerrebroeck, P., Victor, A., & Wein, A. (2003) · Urology · doi:10.1016/s0090-4295(02)02243-4 · Cited by 3,220
Coyne, K. S., Sexton, C. C., Irwin, D. E., Kopp, Z. S., Kelleher, C. J., & Milsom, I. (2008) · BJU International · doi:10.1111/j.1464-410x.2008.07601.x · Cited by 837
SCHURCH, B., STÖHRER, M., KRAMER, G., SCHMID, D. M., GAUL, G., & HAURI, D. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67283-7 · Cited by 822
Chapple, C. R., Khullar, V., Gabriel, Z., Muston, D., Bitoun, C. E., & Weinstein, D. (2008) · European Urology · doi:10.1016/j.eururo.2008.06.047 · Cited by 769
Self-citationCoyne, K. S., Payne, C., Bhattacharyya, S. K., Revicki, D. A., Thompson, C., Corey, R., & Hunt, T. L. (2004) · Value in Health · doi:10.1111/j.1524-4733.2004.74008.x · Cited by 350
Self-citationApostolidis, A., Dasgupta, P., & Fowler, C. J. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.010 · Cited by 347
Karsenty, G., Denys, P., Amarenco, G., De Seze, M., Gamé, X., Haab, F., Kerdraon, J., Perrouin-Verbe, B., Ruffion, A., Saussine, C., et al. (2008) · European Urology · doi:10.1016/j.eururo.2007.10.013 · Cited by 347
Refractory Idiopathic Urge Urinary Incontinence and Botulinum A Injection
Brubaker, L., Richter, H. E., Visco, A., Mahajan, S., Nygaard, I., Braun, T. M., Barber, M. D., Menefee, S., Schaffer, J., Weber, A. M., et al. (2008) · Journal of Urology · doi:10.1016/j.juro.2008.03.028 · Cited by 328
Apostolidis, A., Prokar Dasgupta, A., Denys, P., Elneil, S., Fowler, C. J., Giannantoni, A., Karsenty, G., Schulte‐Baukloh, H., Schurch, B., & Wyndaele, J. (2008) · European Urology · doi:10.1016/j.eururo.2008.09.009 · Cited by 315
Cited by
Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline
Gormley, E. A., Lightner, D. J., Burgio, K. L., Chai, T. C., Clemens, J. Q., Culkin, D. J., Das, A. K., Foster, H. E., Scarpero, H. M., Tessier, C. D., et al. (2012) · Journal of Urology · doi:10.1016/j.juro.2012.09.079 · Cited by 710
Cruz, F., Herschorn, S., Aliotta, P., Brin, M., Thompson, C., Lam, W., Daniell, G., Heesakkers, J., & Haag-Molkenteller, C. (2011) · European Urology · doi:10.1016/j.eururo.2011.07.002 · Cited by 473
Self-citationChapple, C., Sievert, K.-D., MacDiarmid, S., Khullar, V., Radziszewski, P., Nardo, C., Thompson, C., Zhou, J., & Haag-Molkenteller, C. (2013) · European Urology · doi:10.1016/j.eururo.2013.04.001 · Cited by 416
Self-citationClinical guideline for female lower urinary tract symptoms
TAKAHASHI, S., TAKEI, M., NISHIZAWA, O., YAMAGUCHI, O., KATO, K., GOTOH, M., YOSHIMURA, Y., TAKEYAMA, M., OZAWA, H., SHIMADA, M., et al. (2016) · LUTS: Lower Urinary Tract Symptoms · doi:10.1111/luts.12111 · Cited by 47
Metadata
- Authors
- Dmochowski, R., Chapple, C., Nitti, V. W., Chancellor, M., Everaert, K., Thompson, C., Daniell, G., Zhou, J., & Haag-Molkenteller, C.
- Venue
- Journal of Urology
- Published
- 2010-12
- Volume
- 184
- Issue
- 6
- Pages
- 2416-2422
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2157993246
- Cited by
- 406
- References
- 18
- FWCI
- 46.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial. https://app.cochat.ai/papers/10.1016/j.juro.2010.08.021
- The paper
- Dmochowski, R., Chapple, C., Nitti, V. W., Chancellor, M., Everaert, K., Thompson, C., Daniell, G., Zhou, J., & Haag-Molkenteller, C. (2010). Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial. Journal of Urology. https://doi.org/10.1016/j.juro.2010.08.021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
